151 related articles for article (PubMed ID: 9474248)
1. CHOP therapy: has shorter-course therapy had an impact on lymphomas?
Gaynor ER; Fisher RI
Cancer Invest; 1998; 16(1):26-32. PubMed ID: 9474248
[No Abstract] [Full Text] [Related]
2. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):21-5. PubMed ID: 2438778
[TBL] [Abstract][Full Text] [Related]
3. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
4. CHOP versus m-BACOD in non-Hodgkin's lymphoma.
Hryniuk W
N Engl J Med; 1993 Feb; 328(8):581. PubMed ID: 7678920
[No Abstract] [Full Text] [Related]
5. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
6. [Value of MACOP B polychemotherapy for malignant non-Hodgkin's lymphomas in AIDS infected patients].
Taillan B; Ferrari E; Garnier G; Fuzibet JG; Vinti H; Dujardin P
Presse Med; 1992 Feb; 21(6):269. PubMed ID: 1372976
[No Abstract] [Full Text] [Related]
7. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
8. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
9. Primary colorectal T-cell lymphoma.
Okada M; Maeda K; Suzumiya J; Hagimoto T; Wakamatsu S; Ohshima K; Kanda M; Sonoda T; Sakamoto A; Tamura K
J Gastroenterol; 2003; 38(4):376-84. PubMed ID: 12743779
[TBL] [Abstract][Full Text] [Related]
10. The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients.
Adams HJA; Kwee TC
Ann Hematol; 2018 Apr; 97(4):719-720. PubMed ID: 29222579
[No Abstract] [Full Text] [Related]
11. The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution.
Guglielmi C; Amadori S; Martelli M; Papa G; Mandelli F
Leukemia; 1991; 5 Suppl 1():102-4. PubMed ID: 1890858
[No Abstract] [Full Text] [Related]
12. Primary non-Hodgkin's lymphoma of liver with humoral hypercalcaemia.
Santhosh-Kumar CR; Ajarim DS; Shipkey FD
Postgrad Med J; 1990 Aug; 66(778):679-81. PubMed ID: 1699217
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with PROMACE in relapsed non-Hodgkin malignant lymphoma.
Nielsen H
Eur J Haematol; 1991 Feb; 46(2):123-4. PubMed ID: 1995324
[No Abstract] [Full Text] [Related]
14. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
[TBL] [Abstract][Full Text] [Related]
15. Applications of gallium-67 scintigraphy in the management of patients with malignant lymphoma.
Fox K; Silfen D; Alavi A
J Nucl Med; 1991 Dec; 32(12):2299-305. PubMed ID: 1720816
[No Abstract] [Full Text] [Related]
16. [Follicular lymphomas. Therapeutic indications].
Solal-Céligny P
Presse Med; 1992 Apr; 21(14):649-51. PubMed ID: 1534616
[No Abstract] [Full Text] [Related]
17. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
18. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
19. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Alliot C
J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
[No Abstract] [Full Text] [Related]
20. Gall bladder perforation in response to chemotherapy in a patient with a histiocytic lymphoma.
Schaafsma MR; Peters WG; Tham RT; Alleman MJ; Willemze R
Neth J Med; 1988 Aug; 33(1-2):78-82. PubMed ID: 2469970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
